Correction: End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics

Affiliations

• ¹ Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA. annette.medina@astrazeneca.com.
• ² Genentech, Pharmaceutical Development, South San Francisco, CA, 94080, USA.
• ³ Technical Research Development, Novartis Pharma AG, 4002, Basel, Switzerland.
• ⁴ Compassion BioSolution, LLC, Lomita, CA, 90717, USA.
• ⁵ Amgen, Process Development, Thousand Oaks, CA, 91320, USA.
• ⁶ Analytical Development and Attribute Sciences, Bristol Myers Squibb, New Brunswick, NJ, USA.
• ⁷ Pharmaceutical Development, F. Hofmann-La Roche Ltd, CH-4070, Basel, Switzerland.
• ⁸ Drug Product Development, AbbVie, North Chicago, IL, 60064, USA.
• ⁹ Department of Pharmaceutical Sciences & Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, 52242, USA.
• ¹⁰ Dosage Form Design and Development, BioPharmaceuticals Development, R&D, AstraZeneca, 1 Medimmune Way, Gaithersburg, MD, 20878, USA.
• ¹¹ Symbiotix, New York City, NY, 10016, USA.
• ¹² GlaxoSmithKline R&D, Biopharmaceutical Product Sciences, Collegeville, Philadelphia, PA, 19426, USA.